Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 302 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Pelvis Clear all

Conditions: Cancer of the Cervix
Interventions: Granisetron, Ondansetron, Questionnaires, Study Drug Diary; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, goserelin, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions: questionnaire administration, standard follow-up care, educational intervention; Other · Procedure
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 30 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Lymphoceles Following Pelvic Lymph Node Dissection
Interventions: J-Plasma; Device
Lead sponsor: Apyx Medical; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Celebration, Florida

Conditions: Hysterectomy
Interventions: Peritoneal washings; Diagnostic Test
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative, Colostomy, Ileostomy - Stoma, Rectal Prolapse, Intestinal Polyposis, Lymphoma, Endometriosis, Intestinal Volvulus
Interventions: Not listed
Lead sponsor: novoGI; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Atlamonte Springs, Florida • Port Charlotte, Florida • Springfield, Missouri

Conditions: Metastatic Malignant Female Reproductive System Neoplasm
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Volume Modulated Arc Therapy; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Camden, New Jersey • Columbus, Ohio • Houston, Texas

Conditions: Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral, Cancer of the Ureter
Interventions: TRC105; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: 11C Acetate Imaging; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenocarcinoma of the Prostate
Interventions: Pazopanib, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions: Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium; Procedure · Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Prostate Cancer
Interventions: PBRT, PLNRT, AA, LHRH agonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 444
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more

Conditions: Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
Interventions: Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy; Radiation · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
Interventions: Pelvic Floor Muscle Physical Therapy, Control Group; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Ovarian Cancer
Interventions: Biomarker Assay (CA125 and HE4); Device
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Malvern, Pennsylvania • Providence, Rhode Island

Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma, Colon Adenocarcinoma
Interventions: Guardant Reveal; Diagnostic Test
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Lymphedema, Stage IA1 Cervical Cancer AJCC v6 and v7, Stage IA2 Cervical Cancer AJCC v6 and v7, Stage IB1 Cervical Cancer AJCC v6 and v7
Interventions: Conization, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery, Therapeutic Lymphadenectomy; Procedure · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 174
States / cities: Phoenix, Arizona • Auburn, California • Berkeley, California + 136 more

Conditions: Malignancy-induced Pelvic Pain
Interventions: CT-guided Pudendal Nerve Cryoneurolysis, Percutaneous image-guided cryoneurolysis; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, Carcinoma of the Vulva
Interventions: Avastin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenocarcinoma of the Prostate
Interventions: Stereotactic Radiosurgical Boost, Casodex, Leuprolide; Radiation · Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: gemcitabine hydrochloride, cisplatin, gefitinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

Cold Plasma for the Reduction of Lymphoceles Following PLND

Prospective Analysis to Detect Myometrial Cells in Peritoneal Washing in Patients Undergoing Minimally Invasive Hysterectomy Using Containment Bag at University of Texas Medical Branch

A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

11C Acetate Imaging Post Prostatectomy

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Physical Therapy for Men Undergoing Prostatectomy

Risk of Ovarian Cancer in Patients With a Pelvic Mass

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer

CT-guided Pudendal Nerve Cryoneurolysis for Palliation of Malignancy-induced Pelvic Pain

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium